Molecular Diagnostics

Our group is interested in understanding the genomic alterations that drive cancer development, with a focus on DNA testing for early and non-invasive detection of cancer.

We are involved in the development and use of technologies for high-sensitivity detection of mutations, DNA methylation and other genomic alterations that can be used as specific biomarkers for cancer. Recent work includes the development of urine-based tests for detection of bladder cancer and other genitourinary cancers.

Selected publications:

Christensen C, Bartkova J, Mistrik M, Hall A, Lange MK, Ralfkiær U, Bartek J, Guldberg P: A short acidic motif in ARF guards against mitochondrial dysfunction and melanoma susceptibility. Nat Commun 2014;5:5348

Dahl C, Abildgaard C, Riber-Hansen R, Steiniche T, Lade-Keller J, Guldberg P: KIT is a frequent target for epigenetic silencing in cutaneous melanoma. J Invest Dermatol 2015;135(2):516-524

Dahmcke CM, Steven KE, Larsen LK, Poulsen AL, Abdul-Al A, Dahl C, Guldberg P: A prospective blinded evaluation of urine-DNA testing for detection of urothelial bladder carcinoma in patients with gross hematuria. Eur Urol 2016;70(6):916-919

Abildgaard C, Dahl C, Abdul-Al A, Christensen A, Guldberg P: Inhibition of retinoic acid receptor beta signaling confers glycolytic dependence and sensitization to dichloroacetate in melanoma cells. Oncotarget. 2017;8(48):84210-84223

Kirkin AF, Dzhandzhugazyan KN, Guldberg P, Fang JJ, Andersen RS, Dahl C, Mortensen J, Lundby T, Wagner A, Law I, Broholm H, Madsen L, Lundell-Ek C, Gjerstorff MF, Ditzel HJ, Jensen MR, Fischer W: Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells. Nat Commun 2018;9(1):785